IntegenX Awarded DTRA Contract to Develop Pathogen Detection and Identification Platform

PLEASANTON, Calif., Oct. 8 /PRNewswire/ -- IntegenX, Inc. (IXI) today announced that it has been awarded a new contract by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to develop an Integrated Sample-to-Sequence (ISS) system for rapid detection and identification of genetically engineered bacteria and viruses, medically relevant bacteria and viruses, and emerging pathogens. IntegenX will use its Universal Sample Preparation Module (USPM), created under a previous Department of Defense contract, to purify DNA from pathogen targets contained in complex matrices and present the purified material to an IntegenX library construction module, followed by an amplification module and a next-generation sequencing (NGS) module.

IntegenX will be the prime contractor for a first phase of $2.8 million and a possible 22-month, $14.8 million contract. The company will apply its patented MOVe™ technology to integrate the complete workflow of the ISS system, which will have a small footprint of less than 3 cubic feet and will be operated with minimal user interaction by a non-specialist.

"The ISS System will provide DoD and the country with a much-needed system to detect genetically engineered and emerging pathogens. This will help protect our country, and others, against genetically engineered bioagents. There is no system to detect such threats today," said Dr. Stevan Jovanovich, CEO and President of IntegenX.

"Our experience in next-generation sequencing library preparation and making a sample-to-answer system for forensic human identity testing has uniquely positioned IntegenX to accomplish the requirements that DTRA has requested," added Ezra van Gelder, Executive Vice President of Research and Development. "IntegenX technology integrates the processes to incorporate the complex steps into a complete and straightforward sample-to-sequence workflow."

About IntegenX

IntegenX, Inc., headquartered in Pleasanton, CA, is a privately held company that designs, manufactures and markets automated DNA- and RNA-based sample preparation systems for life sciences, applied sciences, and diagnostics markets. IntegenX products eliminate the most acute pain points affecting widely adopted laboratory workflows. The company's expertise and intellectual property is based on its patented MOVe™ valve technology. The microfluidics technology platform integrates advanced fluidics and analytical robotic capabilities to produce sample-to-answer performance for DNA and RNA sequencing, DNA-based forensics and human identity (HID) testing, biodefense, as well as molecular diagnostics applications. The company's first commercial platform, the Apollo 100(TM) System, is used to optimally prepare DNA for sequencing. IntegenX will soon release the Apollo 324 system to resolve the fragmented workflows in next-generation sequencing library preparation. IntegenX has successfully tested a sample-to-answer platform for human DNA identification, slated for commercialization in 2011. For more information, please visit http://www.integenx.com.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE IntegenX, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED